AI Trust Score, Reviews & Company Verification
Is this your company? Claim the Fagron profile to verify ownership and manage company-provided details.
Independent company assessment
8.7/10B · Solid
26 indexed evidence signals reviewed
AI Comparison
Warning Signals76% Confidence
Based on 8 polled AI models
- GPT-5.6OpenAIWarning92%Confidence
- ClaudeAnthropicWarning72%Confidence
- GeminiGoogle DeepMindWarning85%Confidence
- GrokxAIWarning82%Confidence
This profile is waiting for Fagron
Fagron has not claimed this ShouldEye profile yet.
Until an authorized representative verifies ownership, ShouldEye AI independently maintains this overview from public records, reviews, regulatory filings, and live trust signals. Nothing on this page has been approved by the brand.
- Respond to reviews and experiences in your voice
- Replace this placeholder with your official brand message
- Take control of how your trust score is presented
Free verification for authorized company representatives
Fagron is a pharmaceutical company that focuses on optimizing and innovating pharmaceutical compounding to expand the therapeutic options for prescribers worldwide.
- Headquarters
- US
Full intelligence report for Fagron
Fagron demonstrates a strong operational commitment to consumer protection through exceptional customer service, robust legal compliance, and responsible advertising practices that reinforce privacy and domain integrity. However, its comparatively weaker regulatory alignment and market reputation indicate areas of external scrutiny and perceptual friction that contrast with its otherwise solid internal controls. Taken together, these signals shape a verified, broadly trustworthy profile, though the gaps in oversight and public perception warrant modest consumer awareness.
- Clear cancellation process with a 14-day cooling‑off period and transparent fee disclosures in the Terms of Service
- Explicit disclaimer that website content is not medical advice
- Extensive global customer support network with phone, email, web forms, 24/7 pharmacist assistance, and technical resources
- Terms of Service grant Fagron unilateral termination rights, broad indemnification, and ability to modify terms without notice, with exclusive jurisdiction in the Netherlands
- Regulatory exposure includes recurring FDA warning letters for serious manufacturing and quality‑control deficiencies and a past $22.5 million DOJ settlement for inflated drug pricing
- Legal liabilities from lawsuits alleging FDCA violations and a class‑action suit over unsolicited fax advertisements
Public-facing leadership and ownership signals for Fagron — synthesized from verified profiles and corporate disclosures where available.